Invention Grant
US09267119B2 Phosphatidylinositol phosphate kinase type 1 gamma splice variants as biomarkers and drug targets for epithelial cancers
有权
磷脂酰肌醇磷酸激酶1型γ剪接变体作为上皮癌的生物标志物和药物靶标
- Patent Title: Phosphatidylinositol phosphate kinase type 1 gamma splice variants as biomarkers and drug targets for epithelial cancers
- Patent Title (中): 磷脂酰肌醇磷酸激酶1型γ剪接变体作为上皮癌的生物标志物和药物靶标
-
Application No.: US13690903Application Date: 2012-11-30
-
Publication No.: US09267119B2Publication Date: 2016-02-23
- Inventor: Richard A. Anderson , Nicholas J. Schill
- Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
- Applicant Address: US WI Madison
- Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
- Current Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
- Current Assignee Address: US WI Madison
- Agency: Foley & Lardner LLP
- Main IPC: C12N9/12
- IPC: C12N9/12 ; C12Q1/48 ; C12Q1/68 ; G01N33/574
Abstract:
The present invention relates generally to the field of phosphatidylinositol based signaling pathways, and more specifically to the use of novel members of these pathways for disease prognosis and treatment. In some aspects, the present invention relates to the use of novel splice variants of type I phosphatidylinositol phosphate kinase γ, named PIPKIγ 700 and PIPKIγ 707, to determine breast cancer and breast cancer prognosis.
Public/Granted literature
Information query
